RJA
XLO icon

Raymond James & Associates’s Xilio Therapeutics XLO Stock Holding History

Raymond James & Associates’s Portfolio XLO Stock Details XLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$30.6K Hold
2,773
– – ﹤0.01% 3905
2024
Q2 		$36.8K Buy
+2,773
New +$43.4K ﹤0.01% 3826

Other funds holding XLO

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
TPC
Takeda Pharmaceutical Company Tokyo, Japan $16.4M AUM 195.92% 1-Year Est. Return
RVM
RiverVest Venture Management St. Louis, Missouri $6.84M AUM 7.71% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Raymond James & Associates's XLO Position: Q3 2024 in Review

Raymond James & Associates held its Xilio Therapeutics (XLO) position steady in Q3 2024 at 2,773 shares worth $30.6K. The position accounts for ﹤0.01% of the portfolio, ranked #3905.

Raymond James & Associates first reported a position in XLO in Q2 2024 and has held it in 2 quarters since. The position peaked at $36.8K in Q2 2024. 33 funds tracked by Wall St. Rank hold XLO as of Q3 2024.

  • Raymond James & Associates held 2,773 shares of Xilio Therapeutics worth $30.6K as of Q3 2024.
  • Raymond James & Associates left its Xilio Therapeutics share count unchanged in Q3 2024.
  • Xilio Therapeutics made up ﹤0.01% of Raymond James & Associates's portfolio in Q3 2024, its #3905 holding.
  • Raymond James & Associates first reported a position in Xilio Therapeutics in Q2 2024 and has held it in 2 quarters since.
  • Raymond James & Associates's Xilio Therapeutics position peaked at $36.8K in Q2 2024.
  • 33 funds tracked by Wall St. Rank held Xilio Therapeutics as of Q3 2024.

Based on Raymond James & Associates's 13F filing for Q3 2024, filed 18 Oct 2024.